The Chairman of Aurinia Pharmaceuticals (NASDAQ: AUPH) is Buying Shares

By Carrie Williams

Yesterday, the Chairman of Aurinia Pharmaceuticals (AUPHResearch Report), George M Milne, bought shares of AUPH for $65K.

This recent transaction increases George M Milne’s holding in the company by 13% to a total of $590.4K. In addition to George M Milne, one other AUPH executive reported Buy trades in the last month.

See today’s analyst top recommended stocks >>

Based on Aurinia Pharmaceuticals’ latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $50.03 million and GAAP net loss of -$22,556,000. In comparison, last year the company earned revenue of $29K and had a GAAP net loss of $41.02 million. The company has a one-year high of $20.50 and a one-year low of $9.83.

Starting in March 2020, AUPH received 48 Buy ratings in a row. Based on 6 analyst ratings, the analyst consensus is Strong Buy with an average price target of $29.00, reflecting a -55.0% downside. Six different firms, including Bloom Burton and Cantor Fitzgerald, currently also have a Buy rating on the stock.

The insider sentiment on Aurinia Pharmaceuticals has been positive according to 25 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.

Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases particularly lupus nephritis. The company was founded by Robert Foster, Richard Glickman and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.